Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.
Course Instructor
Abby Massey
Capstone Semester
Spring 2022
Date of Graduation
12-16-2022
Abstract
To determine if long-acting injectables cabotegravir and rilpivirine are non-inferior to oral antiretroviral therapy at maintaining viral load suppression below 50 copies per milliliter of serum. Design: Systematic literature review. Methods: A search was done in PubMed using the terms “HIV + cabotegravir” or “HIV + cabotegravir, rilpivirine drug combination.” Limitations included non-randomized control trials, comparison of injectable regimens directly or injectables to placebo, studies that evaluate compliance or side effects only, and studies with small sample sizes. Results: Meta-analysis revealed that continued use of injectables was sufficient in maintaining viral suppression at 93.6%, 92.5%, and 94% in each of the respective studies. This demonstrated non-inferiority to oral therapy. Conclusion: Overall, the three studies randomized participants in oral or long acting therapies after an oral induction period. Long-acting injectable formulations were proven to be non-inferior in the maintenance of viral load suppression. Use of monthly injectable antiretrovirals offers an alternative for increased compliance to many people living with HIV. Efficacy of long-acting injectables as initial therapy and their use in the pediatric population need further study.
Document Type
Capstone
Recommended Citation
Ferrero, A, Naim, N. Use of Long-Acting Injectable Cabotegravir and Rilpivirine in HIV Maintenance Therapy. December 2022.
